Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Insurance Cancer topic
No spam. Unsubscribe anytime.
Senate approves measure to limit insurers’ step‑therapy for metastatic cancer; sponsors later successfully move to return the bill to second reading for an am 1
Summary
Senate Bill 422, designed to limit insurers’ step‑therapy requirements for metastatic cancer, passed second reading after emotional floor testimony; later the Senate voted to reconsider and return the bill to second reading so a negotiated amendment may be added.
Senate Bill 422, which would prohibit insurers from imposing certain step‑therapy ("fail first") requirements on patients with metastatic cancer, passed second reading after sponsors and colleagues described personal experiences with serious illness and the bill’s potential to avoid delays in critical treatments.
Sponsor Senator Boldman described her husband’s experience with stage‑3 testicular cancer and framed the bill as protecting patients from insurer practices that delay access to clinician‑prescribed therapies. She and other supporters said step‑therapy can delay effective treatment, with potentially severe consequences for patients with advanced cancer. Minority Leader Flowers and other senators added personal testimony underscoring the human stakes.
The insurance industry had been an active participant in drafting an amendment; Boldman said she and insurers worked to find compromise language and that the amendment had removed opposition from insurers in the hearing. Majority Leader McGillivray argued against insurance mandates on general principle, saying mandates can raise premiums and increase state subsidy needs, and urged caution.
On the floor the clerk initially recorded 32 senators Aye and 17 Nay; the bill passed second reading. Later in the session Senator Usher offered a motion to reconsider the floor’s action to allow a missing amendment to be attached and formally considered; the Senate adopted the motion to reconsider by a 50–0 voice vote (recorded as 50 Aye). As a result the bill was returned to second reading to receive the additional amendment and further committee/house formatting as needed.
Supporters said the bill — with the amendment negotiated with insurers — places procedural limits on insurers’ step‑therapy practices for metastatic cancer to reduce harmful treatment delays. Opponents cautioned about broader insurance mandate implications for premium costs and regulatory complexity.
